U.S., Dec. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07307274) titled 'A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults' on Nov. 27.

Brief Summary: A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of single and multiple dose regimens of SYNT-101 in healthy and overweight adults.

Study Start Date: Jan. 05, 2026

Study Type: INTERVENTIONAL

Condition: Healthy Overweight and Obese Adults

Intervention: DRUG: SYNT101

Tablet

DRUG: Placebo

Placebo tablet to match SYNT101 in appearance.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Syntis Bio

Discl...